Evidence map›Paper›PMID 32839788›Full record

ArticlemedRxiv : the preprint server for health sciences2020

Engineering luminescent biosensors for point-of-care SARS-CoV-2 antibody detection.

Susanna K Elledge, Xin X Zhou, James R Byrnes, Alexander J Martinko, Irene Lui, Katarina Pance, Shion A Lim, Jeff E Glasgow, Anum A Glasgow, Keirstinne Turcios and 9 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors.

Susanna K ElledgeDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, California, 94158, USA.
Xin X ZhouDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, California, 94158, USA.
James R ByrnesDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, California, 94158, USA.
Alexander J MartinkoSoteria Biotherapeutics, San Francisco, California, 94107, USA.
Irene LuiDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, California, 94158, USA.
Katarina PanceDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, California, 94158, USA.
Shion A LimDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, California, 94158, USA.
Jeff E GlasgowDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, California, 94158, USA.
Anum A GlasgowDepartment of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA, USA.
Keirstinne TurciosDepartment of Medicine, University of California San Francisco, San Francisco, California, 94158, USA.
Nikita IyerDepartment of Medicine, University of California San Francisco, San Francisco, California, 94158, USA.
Leonel TorresDepartment of Medicine, University of California San Francisco, San Francisco, California, 94158, USA.
Michael J PelusoDepartment of Medicine, University of California San Francisco, San Francisco, California, 94158, USA.
Timothy J HenrichDepartment of Medicine, University of California San Francisco, San Francisco, California, 94158, USA.
Taia T WangChan Zuckerberg Biohub, San Francisco, California, 94158, USA.
Cristina M TatoChan Zuckerberg Biohub, San Francisco, California, 94158, USA.
Kevin K LeungDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, California, 94158, USA.
Bryan GreenhouseDepartment of Medicine, University of California San Francisco, San Francisco, California, 94158, USA.
James A WellsDepartment of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, California, 94158, USA.

Funding

Developing, Demonstrating, and Disseminating Innovative Programs to Achieve Translational SuccessUL1TR001866 · NCATS · ROCKEFELLER UNIVERSITY · PI COLLER, BARRY, KRUEGER, JAMES G · 2016 to 2025
$40.6M
Understanding B cell memory in response to diverse virus infectionsU19AI111825 · NIAID · ROCKEFELLER UNIVERSITY · PI NUSSENZWEIG, MICHEL C · 2014 to 2023
$26.0M
RESEARCH TRAINING IN CHEMISTRY AND CHEMICAL BIOLOGYT32GM064337 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CRAIK, CHARLES SCOTT · 2002 to 2021
$7.8M
Training in HIV Translational ResearchT32AI060530 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Diane V Havlir · 2005 to 2026
$6.4M
Targeting Non Viral Markers of HIV PersistenceR01AI141003 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HENRICH, TIMOTHY JENSEN · 2018 to 2022
$4.9M
Regulation of the IgG Fc domain repertoireR01AI139119 · NIAID · STANFORD UNIVERSITY · PI WANG, TAIA · 2019 to 2023
$2.8M
Mentoring translational scientists in international infectious disease researchK24AI144048 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Bryan R Greenhouse · 2019 to 2026
$1.6M
Mapping and rewiring protein allosteryK99GM135529 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GLASGOW, ANUM AZAM · 2020 to 2021
$194k
Characterizing and Targeting the Hypoxic T Cell Surfaceome to Promote Immune Function in CancerF32CA239417 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BYRNES, JAMES ROBERT · 2019 to 2021
$191k
NCATS NIH HHS UL1 TR001866NCI NIH HHS F32 CA239417NIAID NIH HHS R01 AI139119NIAID NIH HHS R01 AI141003NIAID NIH HHS U19 AI111825NIGMS NIH HHS K99 GM135529
6 · The paper itself

Abstract

Current serology tests for SARS-CoV-2 antibodies mainly take the form of enzyme-linked immunosorbent assays or lateral flow assays, with the former being laborious and the latter being expensive and often lacking sufficient sensitivity and scalability. Here we present the development and validation of a rapid, low-cost solution-based assay to detect antibodies in serum, plasma, whole blood, and saliva, using rationally designed split luciferase antibody biosensors (spLUC). This new assay, which generates quantitative results in as short as 5 minutes, substantially reduces the complexity and improves the scalability of COVID-19 antibody tests for point-of-care and broad population testing.

Identifiers

PMID32839788
PMCPMC7444307

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.